Consolidated Statements of Stockholders' Equity - USD ($) |
BioLargo Energy Technologies, Inc (BETI) [Member]
Common Stock [Member]
|
BioLargo Energy Technologies, Inc (BETI) [Member]
Additional Paid-in Capital [Member]
|
BioLargo Energy Technologies, Inc (BETI) [Member]
Retained Earnings [Member]
|
BioLargo Energy Technologies, Inc (BETI) [Member]
AOCI Attributable to Parent [Member]
|
BioLargo Energy Technologies, Inc (BETI) [Member]
Noncontrolling Interest [Member]
|
BioLargo Energy Technologies, Inc (BETI) [Member] |
Clyra Medical Technologies [Member]
Clyra Medical Preferred Stock, Series B [Member]
Common Stock [Member]
|
Clyra Medical Technologies [Member]
Clyra Medical Preferred Stock, Series B [Member]
Additional Paid-in Capital [Member]
|
Clyra Medical Technologies [Member]
Clyra Medical Preferred Stock, Series B [Member]
Retained Earnings [Member]
|
Clyra Medical Technologies [Member]
Clyra Medical Preferred Stock, Series B [Member]
AOCI Attributable to Parent [Member]
|
Clyra Medical Technologies [Member]
Clyra Medical Preferred Stock, Series B [Member]
Noncontrolling Interest [Member]
|
Clyra Medical Technologies [Member]
Clyra Medical Preferred Stock, Series B [Member]
|
Clyra Medical Technologies [Member]
Common Stock [Member]
|
Clyra Medical Technologies [Member]
Additional Paid-in Capital [Member]
|
Clyra Medical Technologies [Member]
Retained Earnings [Member]
|
Clyra Medical Technologies [Member]
AOCI Attributable to Parent [Member]
|
Clyra Medical Technologies [Member]
Noncontrolling Interest [Member]
|
Clyra Medical Technologies [Member] |
Common Stock [Member] |
Additional Paid-in Capital [Member] |
Retained Earnings [Member] |
AOCI Attributable to Parent [Member] |
Noncontrolling Interest [Member] |
Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance (in shares) at Dec. 31, 2023 | 292,945,747 | |||||||||||||||||||||||
| Balance at Dec. 31, 2023 | $ 196,000 | $ 154,023,000 | $ (147,098,000) | $ (277,000) | $ (2,642,000) | $ 4,202,000 | ||||||||||||||||||
| Stock for cash, net offering costs (in shares) | 2,614,895 | |||||||||||||||||||||||
| Stock for cash, net offering costs | $ 2,000 | 592,000 | 0 | 0 | 0 | $ 594,000 | ||||||||||||||||||
| Issuance of stock for services (in shares) | 1,107,594 | 1,107,594 | ||||||||||||||||||||||
| Issuance of stock for services | $ 1,000 | 283,000 | 0 | 0 | 0 | $ 284,000 | ||||||||||||||||||
| Issuance of common stock in exchange for BETI shares (in shares) | 378,788 | |||||||||||||||||||||||
| Issuance of common stock in exchange for BETI shares | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | ||||||||||||||||||
| Warrant exercise (in shares) | 3,278,337 | |||||||||||||||||||||||
| Warrant exercise | $ 3,000 | 753,000 | 0 | 0 | 0 | 756,000 | ||||||||||||||||||
| Stock option compensation expense | $ 0 | 1,535,000 | 0 | 0 | 0 | 1,535,000 | ||||||||||||||||||
| Stock option exercise (in shares) | 948,882 | |||||||||||||||||||||||
| Stock option exercise | $ 0 | 153,000 | 0 | 0 | 0 | 153,000 | ||||||||||||||||||
| Clyra Medical stock option compensation expense | $ 0 | $ 0 | $ 0 | $ 0 | $ 528,000 | $ 528,000 | ||||||||||||||||||
| Clyra Medical stock issued for services | 0 | 0 | 0 | 0 | 132,000 | 132,000 | ||||||||||||||||||
| Clyra Medical dividend Series A Preferred stock | 0 | 0 | 0 | 0 | (345,000) | (345,000) | ||||||||||||||||||
| Clyra Medical warrant exercise | 0 | 0 | 0 | 0 | 30,000 | 30,000 | ||||||||||||||||||
| Clyra Medical warrant fee | 0 | 0 | 0 | 0 | 106,000 | 106,000 | ||||||||||||||||||
| Clyra Medical stock unit offering | 0 | 0 | 0 | 0 | 2,005,000 | 2,005,000 | ||||||||||||||||||
| Clyra Medical conversion of note payable and interest | 0 | 0 | 0 | 0 | 119,000 | 119,000 | ||||||||||||||||||
| Clyra Medcial fair value of warrants issued with note payable | 0 | 0 | 0 | 0 | 160,000 | 160,000 | ||||||||||||||||||
| BETI unit offering | $ 0 | 0 | 0 | 0 | 50,000 | 50,000 | ||||||||||||||||||
| Noncontrolling interest allocation | 0 | 993,000 | 0 | 0 | (993,000) | 0 | ||||||||||||||||||
| Net loss | 0 | 0 | (2,402,000) | 0 | (1,945,000) | (4,347,000) | ||||||||||||||||||
| Foreign currency translation adjustment | $ 0 | 0 | 0 | 94,000 | 0 | 94,000 | ||||||||||||||||||
| Balance (in shares) at Dec. 31, 2024 | 301,274,243 | |||||||||||||||||||||||
| Balance at Dec. 31, 2024 | $ 202,000 | 158,332,000 | (149,500,000) | (183,000) | (2,795,000) | 6,056,000 | ||||||||||||||||||
| Stock for cash, net offering costs (in shares) | 12,876,702 | |||||||||||||||||||||||
| Stock for cash, net offering costs | $ 9,000 | 2,018,000 | 0 | 0 | 0 | $ 2,027,000 | ||||||||||||||||||
| Issuance of stock for services (in shares) | 2,807,771 | 2,807,771 | ||||||||||||||||||||||
| Issuance of stock for services | $ 2,000 | 555,000 | 0 | 0 | 0 | $ 557,000 | ||||||||||||||||||
| Issuance of common stock in exchange for BETI shares (in shares) | 153,261 | |||||||||||||||||||||||
| Issuance of common stock in exchange for BETI shares | $ 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||
| Stock option compensation expense | $ 0 | 1,762,000 | 0 | 0 | 0 | 1,762,000 | ||||||||||||||||||
| Stock option exercise (in shares) | 265,800 | |||||||||||||||||||||||
| Stock option exercise | $ 0 | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||||
| Clyra Medical stock option compensation expense | 0 | 0 | 0 | 0 | 1,203,000 | 1,203,000 | ||||||||||||||||||
| Clyra Medical stock issued for services | 0 | 0 | 0 | 0 | 76,000 | 76,000 | ||||||||||||||||||
| Clyra Medical dividend Series A Preferred stock | 0 | 0 | 0 | 0 | (347,000) | (347,000) | ||||||||||||||||||
| Clyra Medical stock unit offering | $ 0 | $ 0 | $ 0 | $ 0 | $ 2,145,000 | $ 2,145,000 | 0 | 0 | 0 | 0 | 445,000 | 445,000 | ||||||||||||
| Clyra Medcial fair value of warrants issued with note payable | 0 | 0 | 0 | 0 | 231,000 | 231,000 | ||||||||||||||||||
| BETI unit offering | 0 | 0 | 0 | 0 | 425,000 | 425,000 | ||||||||||||||||||
| Noncontrolling interest allocation | 0 | 2,649,000 | 0 | 0 | (2,649,000) | 0 | ||||||||||||||||||
| Net loss | 0 | 0 | (11,780,000) | 0 | (3,409,000) | (15,189,000) | ||||||||||||||||||
| Foreign currency translation adjustment | $ 0 | 0 | 0 | (24,000) | 0 | (24,000) | ||||||||||||||||||
| Clyra Medical stock issued to convert debt | 0 | 0 | 0 | 0 | 250,000 | 250,000 | ||||||||||||||||||
| Clyra Medical Unit Warrant offering | $ 0 | $ 0 | $ 0 | $ 0 | $ 1,894,000 | $ 1,894,000 | ||||||||||||||||||
| BETI stock issued for services | $ 0 | $ 0 | $ 0 | $ 0 | $ 15,000 | $ 15,000 | ||||||||||||||||||
| Balance (in shares) at Dec. 31, 2025 | 317,377,777 | |||||||||||||||||||||||
| Balance at Dec. 31, 2025 | $ 213,000 | $ 165,316,000 | $ (161,280,000) | $ (207,000) | $ (2,516,000) | $ 1,526,000 |